MANUFACTURING ARTICLES

• From Supporting Component to Strategic Driver: The Evolving Role of gRNA in CRISPR Therapeutics

  Guide RNA is evolving from a simple targeting reagent into a complex, engineered molecule shaped by expanding CRISPR modalities, increasing length and modification demands, and tighter integration with manufacturability, analytical control, and regulatory expectations.

• A Novel Co-Tethered Transcription Platform For High-Yield, High-Purity mRNA Synthesis

  Co-tethered transcription boosts mRNA yield and purity by organizing transcription machinery, reducing dsRNA impurities, and streamlining production for scalable RNA therapeutics.

• A New Approach To RNA Synthesis And Purification: Rethinking A Persistent Bottleneck

  Photocleavable supports enable light-triggered RNA release, reducing reliance on chromatography and streamlining synthesis, scalability, and purity for complex RNA therapeutics.

• Oligos, mRNA, Or Gene Editing: Where Should You Bet?

  Investing in RNA and gene editing requires balancing risk, timing, and scale — understanding how oligos, mRNA, and CRISPR each drive value across a converging biotech landscape.

• Beyond The Gold Standard(s): Modernizing Oligonucleotide Synthesis

  A few weeks ago, I had the chance to sit down with OPT Congress speaker Phil Baran, Richard Lerner Chair Professor, Department of Chemistry, Scripps Research. Baran was slated to (and did) present a keynote on the innovations shaping the next generation of oligo synthesis. Here, I share the biggest takeaways I had from our conversation, touching on how he sees the science of oligo chemistry and manufacturing advancing in the near and far future. 

• The RNA Ties That Bind: 3 Takeaways From The OPT Congress

  Here, I unpack three takeaways I had from the OPT Congress, each of which I’d argue are indicative of the interconnectedness across the genetic medicines field.